NCT05393388

Tau Pet Imaging in the Aging Brain Cohort Dedicated to Diversity Study

• Status: Active Not Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 111 (actual)
• Sponsor: University of Pennsylvania · Academic / Other
• Sex: All
• Age: 65 Years
• Healthy volunteers: Accepted

Summary

We will conduct a Tau PET scan in cognitively normal older adults, enrolled in the Aging Brain Cohort Dedicated to Diversity Study (ABCD2-Tau) study at the University of Pennsylvania's Penn Memory Center/Alzheimer's Disease Core Center (PMC/ADC).Study duration will generally be a one-day study visit for PET imaging, but all subjects will be followed annually as part of their participation in the ABCD2 study. Findings from this study will likely provide insight into the mechanisms and distinctions of age-related cognitive decline and that of preclinical Alzheimer's Disease.

Conditions

• Cognitive Decline
• Alzheimer Disease

Interventions

Type	Name	Description
DRUG	[18F]AV-1451	\[18F\]AV-1451 has been developed as a positron emitting radiopharmaceutical for in vivo imaging of tau protein aggregates.

Timeline

• Start date: 2022-07-06
• Primary completion: 2027-05-01
• Completion: 2027-05-01
• First posted: 2022-05-26
• Last updated: 2025-11-26

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study